Compare
Biogen vs Pfizer
MonkScore ranges and fundamentals, side by side
Key facts
Biogen and Pfizer: key facts
- In fiscal 2025, Biogen Inc. reported revenue of $9.8B and net income of $1.3B.
- In fiscal 2025, Pfizer Inc. reported revenue of $62.6B and net income of $7.8B.
- Biogen Inc.'s revenue fell 2.8% a year from fiscal 2021 to fiscal 2025.
- Pfizer Inc.'s revenue fell 6.3% a year from fiscal 2021 to fiscal 2025.
- Biogen Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Pfizer Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Biogen Inc. reported revenue of $10.3B and net income of $348.0M.
- In the twelve months to 28 June 2026, Pfizer Inc. reported revenue of $63.7B and net income of $4.3B.
Side by side
Biogen and Pfizer, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Biogen Inc.NASDAQ:BIIB | Pfizer Inc.NYSE:PFE |
|---|---|---|
| MonkScore | ||
| MonkScore range | 50–60as of October 2026 | 20–30as of October 2026 |
| Sector rank | 352 of 628 in Healthcare | 520 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $9.8BFY 2025 | $62.6BFY 2025 |
| Net income | $1.3BFY 2025 | $7.8BFY 2025 |
| Free cash flow | $2.1BFY 2025 | $9.1BFY 2025 |
| Operating cash flow | $2.2BFY 2025 | $11.7BFY 2025 |
| Total debt | $6.9BFY 2025 | $67.4BFY 2025 |
| Cash | $3.0BFY 2025 | $1.1BFY 2025 |
| Last 12 months | ||
| Revenue | $10.3Bto 30 September 2026 | $63.7Bto 28 June 2026 |
| Net income | $348.0Mto 30 September 2026 | $4.3Bto 28 June 2026 |
| Free cash flow | $2.3Bto 30 September 2026 | $11.0Bto 28 June 2026 |
| Operating cash flow | $2.2Bto 30 September 2026 | $13.4Bto 28 June 2026 |
| Total debt | $7.8Bto 30 September 2026 | $63.2Bto 28 June 2026 |
| Cash | $1.3Bto 30 September 2026 | $976.0Mto 28 June 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.